|
Chemotherapy in Treating Patients With Recurrent Malignant Glioma Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about Chemotherapy in Treating Patients With Recurrent Malignant Glioma conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Chemotherapy in Treating Patients With Recurrent Malignant Glioma Clinical research trials and Chemotherapy in Treating Patients With Recurrent Malignant Glioma healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as Chemotherapy in Treating Patients With Recurrent Malignant Glioma. Chemotherapy in Treating Patients With Recurrent Malignant Glioma Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Chemotherapy in Treating Patients With Recurrent Malignant Glioma clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their Chemotherapy in Treating Patients With Recurrent Malignant Glioma condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Chemotherapy in Treating Patients With Recurrent Malignant Glioma  Chemotherapy in Treating Patients With Recurrent Malignant Glioma
Chemotherapy in Treating Patients With Recurrent Malignant Glioma
For Condition: recurrent adult brain tumor
Status: No longer recruiting
Sponsor(s): Duke Comprehensive Cancer Center ,
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of topotecan plus carmustine in patients with recurrent primary malignant glioma.
Details: OBJECTIVES: - Determine the maximum tolerated dose of topotecan administered in combination with a fixed dose of carmustine. - Determine the toxic effects of topotecan and carmustine in patients with recurrent primary malignant glioma. OUTLINE: Topotecan is administered by an ambulatory infusion pump for 72 hours each week. Topotecan dose escalation is carried out in cohorts of three patients. Dose escalation is continued until toxic effects or disease progression is observed in these patients. Carmustine is administered over 1 hour every 6 weeks, on the same day as the first topotecan dose for that week. Three patients will be treated at an initial dose level of topotecan, and if one of these patients experience dose limiting toxicity (DLT), an additional 3 patients must be treated at this dose level without further DLT in order for dose escalation to proceed. The MTD is the highest dose at which DLT occurs in no more than 1 of 6 patients. Patients are evaluated after every 6 week cycle. PROJECTED ACCRUAL: An estimated 18-36 patients will be entered.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically proven recurrent primary malignant glioma - Measurable recurrent or residual primary central nervous system neoplasm confirmed by MRI PATIENT CHARACTERISTICS: Age: - 18 and over Performance Status: - Karnofsky at least 60% Hematopoietic: - Hematocrit greater than 29% - ANC greater than 1,500/mm^3 - Platelet count greater than 125,000/mm^3 Hepatic: - SGOT less than 1.5 times upper limit of normal (ULN) - Bilirubin less than 1.5 times ULN Renal: - Creatinine less than 1.5 mg/dL - BUN less than 25 mg/dL Other: - Not pregnant - Effective contraceptive method must be used for the duration of the study PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - No prior chemotherapy within 6 weeks of study - No prior topotecan or carmustine treatment failure - No more than 1 prior chemotherapy regimen Endocrine therapy: - Patients taking corticosteroids must be on stable dose for at least 2 weeks prior to study and the dose should not escalate over entry level Radiotherapy: - No prior radiotherapy within 6 weeks of study Surgery: - No prior surgical resection within 3 weeks of study Other: - No concurrent medication that may interfere with study results
Total Enrollment:
Location and Contact Information:
Overall Study Official:
HenryFriedman, Study Chair, Duke Comprehensive Cancer Center
Duke Comprehensive Cancer Center
Durham, North Carolina, 27710
United States
Saint Jude Children's Research Hospital
Memphis, Tennessee, 38105-2794
United States
Additional Information:
Study ID Numbers: CDR0000065521; DUMC-000224-01-1R4,DUMC-000224-00-2R3,DUMC-0348-99-2R2,DUMC-223-97-2,DUMC-229-98-2R1,SB-DUMC-229-98-2R1,NCI-G97-1242
Study Start Date:
Record last reviewed: April 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002986
Other Recurrent Adult Brain Tumor Studies:
1. Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas
2. Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma
3. Karenitecin in Treating Patients With Recurrent Malignant Glioma
4. O(6)-benzylguanine in Treating Patients With Malignant Glioma
5. Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma
Related Studies:
Other recurrent adult brain tumor Clinical Trials
Other North Carolina Clinical Trials
Other Durham Clinical Trials
Chemotherapy in Treating Patients With Recurrent Malignant Glioma
|
|
|
|
|
|
|
|
